DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced that Todd Cooper, President and CEO, is scheduled to present at the Rodman & Renshaw 19th Annual Investment Conference. The Conference will take place at the Lotte New York Palace Hotel in New York City from September 10 to 12, 2017. Mr. Cooper will be available for one-on-one meetings.
The presentation will provide an update on the status of the U.S. clinical trial. "Presbia plans on submitting the fourth and final module of the IDE study to the FDA in Q4, which is a major milestone towards approval of the Presbia Flexivue Microlens™ in the U.S.," said Mr. Cooper.
Details of the presentation are as follows:
Date: Monday, September 11, 2017
Time: 3:50 PM ET
Room: Louis (4th Floor)
Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.